In breast cancer therapy, estrogen receptor alpha (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status of the primary tumor have become the major determinants of targeted treatment regimens [5]. This evidence concerns the gene PGR and breast cancer.